Sonnet Biotherapeutics Holdings Inc expected to post a loss of 76 cents a share - Earnings Preview
09/08/2024 19:32
* Sonnet Biotherapeutics Holdings Inc SONN.OQ SONN.O is
expected to show a fall in quarterly revenue when it reports
results on August 12 (estimated) for the period ending June
30 2024
* The Princeton New Jersey-based company is expected to
report a
23.0% decrease in revenue to $28.5 thousand from $37 thousand a
year ago, according to the mean estimate from 2 analysts, based
on LSEG data.
* LSEG's mean analyst estimate for Sonnet Biotherapeutics
Holdings Inc is for a loss of 76 cents per share.
* The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 3 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Sonnet
Biotherapeutics Holdings Inc is $30.00, above its last closing
price of $0.74.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Mar. 31 2024 0.19 0.14 0.07 Missed -48.1
Dec. 31 2024 -0.90 -0.90 -0.31 Beat 65.6
Sep. 30 2023 -2.60 -4.09 -2.09 Beat 48.9
Jun. 30 2023 -6.82 -2.86 Beat 58.1
Mar. -10.29 -10.89 -7.48 Beat 31.3
31 2023
Dec. 31 2022 -24.20 -24.20 -17.60 Beat 27.3
Sep. 30 2022 -33.22 -33.22 -36.74 Missed -10.6
Jun. 30 2022 -43.31 -43.12 -40.04 Beat 7.1
This summary was machine generated August 9 at 18:32 GMT. All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)